Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

service design

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

FDA proposes improvements for oncology clinical trials supporting accelerated approval

The draft guidance discusses the advantage of randomised clinical trials over single-arm studies

- PMLiVE

AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer

More than 52,000 men are diagnosed with prostate cancer every year in the UK alone

- PMLiVE

Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study

The treatment is already approved in the US for three disease states of prostate cancer

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

- PMLiVE

Janssen’s single tablet combination shows promise in phase 3 PAH study

Around 500 to 1,000 cases of pulmonary arterial hypertension are diagnosed each year in the US

- PMLiVE

What are design systems and how can they help you elevate your digital products?

Design Systems aren’t new, but the potential to utilise them to improve the way in which teams produce digital products is still untapped for many in the pharmaceutical and healthcare...

Graphite Digital

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

Streamlining Healthcare Delivery Through Digital Care Journeys

Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,...

Impetus Digital

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links